News on research and diagnostics in autoimmune disorders including rheumatoid arthritis, lupus, multiple sclerosis, and more.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The assay is for diagnosing lupus and is the second immunofluorescence assay cleared by the FDA for the Helios platform.
The firm said that with its mimetope peptide assays, which measure the concentration of blood in a sample, patients would receive the right dose of the right drug.
The new deal expands an earlier agreement and allows Immunodiagnostic to sell assays developed by Technogenetics under the IDS brand.
In studies of 140 multiple sclerosis patients and controls, the researchers identified two blood-based metabolites as potential markers of the disease.
